Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry.
Van Voorhees AS, Mason MA, Harrold LR, Guo N, Guana A, Tian H, Herrera V, Strober BE. Van Voorhees AS, et al. Among authors: guana a. J Dermatolog Treat. 2021 May;32(3):302-309. doi: 10.1080/09546634.2019.1656797. Epub 2019 Oct 3. J Dermatolog Treat. 2021. PMID: 31581919 Free article.
Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study.
Puig L, Augustin M, Blauvelt A, Gottlieb AB, Vender R, Korman NJ, Thaçi D, Zhao Y, Gilloteau I, Sherif B, Williams N, Guana A, Lebwohl MG. Puig L, et al. Among authors: guana a. J Am Acad Dermatol. 2018 Apr;78(4):741-748. doi: 10.1016/j.jaad.2017.10.025. Epub 2017 Oct 21. J Am Acad Dermatol. 2018. PMID: 29066271 Clinical Trial.
Secukinumab demonstrates superior efficacy and a faster response in clearing skin in Asian subjects with moderate to severe plaque psoriasis compared with ustekinumab: Subgroup analysis from the CLEAR study.
Lee MG, Huang YH, Lee JH, Lee SC, Kim TG, Aw DC, Bao W, Dee CMA, Guana A, Tsai TF. Lee MG, et al. Among authors: guana a. J Dermatol. 2019 Sep;46(9):752-758. doi: 10.1111/1346-8138.15004. Epub 2019 Jul 25. J Dermatol. 2019. PMID: 31342560 Clinical Trial.
Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.
Bissonnette R, Luger T, Thaçi D, Toth D, Messina I, You R, Guana A, Fox T, Papavassilis C, Gilloteau I, Mrowietz U. Bissonnette R, et al. Among authors: guana a. Br J Dermatol. 2017 Oct;177(4):1033-1042. doi: 10.1111/bjd.15706. Epub 2017 Sep 4. Br J Dermatol. 2017. PMID: 28580579 Clinical Trial.
Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study.
Thaçi D, Puig L, Reich K, Tsai TF, Tyring S, Kingo K, Ziv M, Pinter A, Vender R, Lacombe A, Xia S, Bhosekar V, Gilloteau I, Guana A, Blauvelt A. Thaçi D, et al. Among authors: guana a. J Am Acad Dermatol. 2019 Dec;81(6):1405-1409. doi: 10.1016/j.jaad.2019.04.045. Epub 2019 Aug 6. J Am Acad Dermatol. 2019. PMID: 31399223 Free article. Clinical Trial. No abstract available.
Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
Blauvelt A, Reich K, Mehlis S, Vanaclocha F, Sofen H, Abramovits W, Zhao Y, Gilloteau I, Davenport E, Williams N, Guana A, Tyring S. Blauvelt A, et al. Among authors: guana a. J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1693-1699. doi: 10.1111/jdv.14391. Epub 2017 Aug 8. J Eur Acad Dermatol Venereol. 2017. PMID: 28602039 Free PMC article. Clinical Trial.
24 results